OpenEvidence, an artificial intelligence platform used by more than 40% of U.S. physicians, is reportedly in talks to raise $200 million at a $20 billion valuation. The potential round would mark a significant step for the company, which has become a go-to tool for doctors seeking quick, reliable clinical information.
The AI platform behind the numbers
OpenEvidence offers a search engine-like interface trained on medical literature, drug databases, and clinical guidelines. Instead of returning a list of links, it generates concise, cited answers to questions a doctor might type in — such as drug interactions or treatment protocols. The company says its system is designed to reduce the time physicians spend hunting for information, a task that can eat up hours each day.
The reported valuation — $20 billion — would place OpenEvidence among the most valuable private AI companies in healthcare. For context, that is roughly on par with the market caps of some publicly traded health-tech firms. The $200 million figure suggests the round is not a massive primary raise but rather a targeted injection, possibly to accelerate product development or expand into new markets.
Why investors are paying attention
Healthcare has been a stubborn sector for AI adoption. Many tools promise to save time but fail to integrate into the daily workflow of clinicians. OpenEvidence appears to have cracked that code, at least in part. Its user base — over 40% of U.S. physicians — is a rare metric in an industry where even well-funded startups struggle to get doctors to log in more than once.
The company does not disclose revenue figures, but the high valuation implies strong investor confidence in its growth trajectory. The round would also signal that venture capital remains willing to bet big on AI in healthcare, despite a broader slowdown in tech funding.
What the funding would mean
If the deal closes, OpenEvidence would have fresh capital to invest in its technology and sales team. The company could also use the money to build out features that go beyond simple Q&A — such as integration with electronic health records or automated clinical decision support. Competitors in the space include UpToDate, a Wolters Kluwer product, and newer entrants like Doximity's AI tools.
But a $20 billion valuation also raises the bar. The company will need to show it can convert its physician user base into a sustainable business, likely through subscription fees paid by hospitals or health systems. So far, OpenEvidence has not commented on the reported funding talks.
The next step is whether the company confirms the round and, if so, how it plans to deploy the cash. For now, the number that matters is 40% — the share of U.S. doctors already using the platform. That is a foundation most health-tech startups would envy.
